(iii) IDH1 and IDH2 mutations are also rarely present in preleukemic myeloid malignancies: 0.8–4% in chronic phase MPN, 4–14% in MDS, but its frequency increases up to 20–25% in blast phase transformation [40–43]. Here, IDH2 is linked to myeloid neoplasm.